Phenelzine sulfate	-	HDM inhibitor/monoamine oxidase A inhibitor	Phase 2	Ongoing	Non-metastatic recurrent prostate cancer	Study completion date: August 2018	NCT02217709
Phenelzine sulfate	Docetaxel	HDM inhibitor/monoamine oxidase A inhibitor	Phase 2	Ongoing	Progressive prostate cancer	Final data collection date for primary outcome measure: January 2016	NCT01253642
OGX-011	Docetaxel/prednisone	Antisense oligonucleotide that targets clusterin	Phase 1	Completed	advanced cancer including prostate, bladder and kidney cancer	Six patients with hormone-refractory prostate cancer had a PSA decline >=50%	Saad et al. 2011 (NCT00471432)
OGX-011	Docetaxel/prednisone and docetaxel/mitoxantrone	Antisense oligonucleotide that targets clusterin	Phase 3	Completed	MCRPC	No objective responses were seen 41% of the patients discontinued treatment due to serious adverse events	Chi et al. 2008 (NCT01188187)
OGX-011	Cabazitaxel/prednisone	Antisense oligonucleotide that targets clusterin	Phase 3	Ongoing	CRPC	Study completion date: December 2016	NCT01578655
Oblimersen	Docetaxel	Antisense oligonucleotide that targets Bcl-2	Phase 2	Completed	CRPC	PSA response was observed in 46% and 37% of the patients treated with docetaxel alone and docetaxel+oblimersen, respectivelyPartial response was observed in 18% and 24% of the patients in the referred groups and major toxic events were reported in 22,8% and 40,7% respectively	Sternberq et al. 2009 (NCT00085228)
Oblimersen sodium (Genasense)	Mitoxantrone	Antisense oligonucleotide that targets Bcl-2	Phase 1	Completed	CRPC	Two patients had a PSA reduction >=50%, 1 patient had a PSA resuction <50%, and 5 patients had stable disease	Chi et al. 2001
OGX-427	Prednisone	Antisense oligonucleotide that targets heat shock protein27	Phase 2	Completed	CRPC	No study results or publications provided	NCT01120470
OGX-427	Abiraterone	Antisense oligonucleotide that targets heat shock protein27	Phase 2	Ongoing	MCRPC	Study completion date: December 2017	NCT01681433
ISIS 1837	Docetaxel/prednisone	Antisense oligonucleotide that targets eIF4E	Phase 2	Completed	Metastatic resistant castrate prostate cancer	No study results or publications provided	EudraCT Number: 2010-022239-12
ISIS 3521/ISIS 5132	-	Antisense oligonucleotides that targets PKC-α and Raf-1, respectively	Phase 2	Completed	CRPC	No objective responses were observed but three patients had stable disease for 5 or more months PSA values of five patients did not rise more than 25% for >=120 days	Tolcher et al. 2002
LY2181308	Docetaxel/prednisone	Antisense oligonucleotide that targets survivin	Phase 2	Completed	CRPC	No differences in efficacy were observed between the control and the experimental group. Higher incidence of adverse effects in the LY2181308 treated group.	Wiechno et al. 2014